Neuralink
Developing ultra-high bandwidth brain-computer interfaces to restore human autonomy and visual perception.
Company FactsPrivately Held
Neuralink Neurotechnology Architecture & Clinical Programs
In-depth technical breakdown of the N1 Telepathy brain implant, the R1 Surgical Insertion Robot, the Blindsight visual cortex program, and active FDA / Health Canada clinical trials. Every specification is verified against official Neuralink disclosures.
N1 Implant (Telepathy): Technical Specifications & Functionality
Hermetically sealed 1,024-channel intracortical neural interface mounted flush with the human skull.
Distributed across 64 ultra-fine flexible polymer threads (16 electrodes per thread).
Width ranges 5–50 µm; significantly thinner than a human hair (~70 µm).
Biocompatible titanium casing sealed hermetically; sits flush within cranial bone.
Transcutaneous wireless charging puck; low-latency radio streaming to user devices.
Real-Time On-Chip Neural Processing
The N1 Implant integrates a proprietary low-power application-specific integrated circuit (ASIC). The chip amplifies, bandpass filters, and digitizes analog microvolt signals recorded from the motor cortex. It performs on-device spike detection and neural firing rate estimation before wirelessly transmitting compressed telemetry data to external hardware.
This on-device processing minimizes radio bandwidth requirements and reduces power consumption, allowing continuous all-day operation on an internal battery charged via a magnetic inductive puck through the scalp.
Restoring Digital Autonomy (Telepathy)
In human clinical participants with quadriplegia, the N1 Implant translates the intention to move limbs into digital commands. Neural signals from the primary motor cortex (M1) are mapped to 2D and 3D computer cursor control, enabling participants to browse the web, compose messages, play PC video games, and operate professional design software without physical movement.
In official clinical trial reports, participants demonstrated independent gameplay in Civilization VI and Counter-Strike 2, as well as 3D computer-aided design (CAD) modeling for custom assistive hardware brackets.
Official Report: PRIME Second Participant ProgressR1 Surgical Robot: Automated Implantation Procedure & Mechanism
Computer-vision-guided robotic system designed to insert flexible neural threads while avoiding cortical blood vessels.
A neurosurgeon creates a circular opening (~23 mm) in the cranium over the precentral gyrus motor area, exposing the dura and cortical surface.
R1’s 5-camera optical stack and optical coherence tomography (OCT) track the brain surface in real-time to compensate for respiratory and cardiac pulsation.
Computer vision algorithms map pial and cortical micro-vessels, autonomously calculating needle paths that bypass blood vessels to avoid intracranial bleeding.
A 10–15 µm needle inserts threads individually to a depth of ~1.5–2 mm into cortical layers IV–V. The 64 insertions complete in approximately 20–25 minutes.
Because Neuralink’s polyimide threads are flexible and only 4 to 6 microns thick, they cannot be pushed into brain tissue by hand; any manual mechanical force causes the thread to buckle. The R1 Robot uses a rigid microscopic needle tip that engages a tiny loop at the end of each thread, carries it to target depth with sub-millimeter axial precision, and releases it before retracting.
Blindsight: Vision Restoration Program & Regulatory Status
Cortical neuro-prosthesis engineered to bypass damaged eyes and optic nerves by directly stimulating the visual cortex.
Positioned in the occipital lobe at the rear of the brain, directly stimulating visual neurons mapped to retinotopic coordinate fields.
Designed for patients who have lost both eyes, suffered complete optic nerve transection, or have non-functional retinas.
Granted by the U.S. FDA in September 2024 to expedite scientific review, clinical trial protocol clearance, and manufacturing pathways.
Mechanism of Phosphene Perception & Resolution Scaling
By micro-stimulating discrete clusters of neurons in the visual cortex, Blindsight elicits “phosphenes”—perceived points of light in the visual field. When driven by external digital cameras, matrices of electrodes stimulate coordinated phosphenes to recreate synthetic vision.
According to company technical disclosures, initial visual resolution will resemble low-resolution retro graphics (enabling light, shape, and obstacle navigation), but is engineered to scale over time toward natural resolution as electrode count increases.
PRIME & CAN-PRIME Clinical Trials: Status, Locations & Enrollment
Authorized clinical feasibility studies evaluating the safety and functional utility of the N1 Implant and R1 Robot.
PRIME Study (United States)
Full Name: Precise Robotically Implanted Brain-Computer Interface (PRIME)
Regulatory Authority: U.S. Food and Drug Administration (FDA) under Investigational Device Exemption (IDE).
Primary Surgical Center: Barrow Neurological Institute (Phoenix, Arizona, USA).
Target Cohort: Individuals with quadriplegia caused by cervical spinal cord injury (C4–C7 levels) or Amyotrophic Lateral Sclerosis (ALS).
Enrolled Participants Status: Multiple human participants actively implanted and testing motor control software.
CAN-PRIME Study (Canada)
First International Expansion: Approved by Health Canada in November 2024 to commence clinical trial operations.
Authorized Clinical Partner: University Health Network (UHN) / Toronto Western Hospital (Toronto, Ontario, Canada).
Surgical Scope: Clinical feasibility evaluation of R1 surgical precision and N1 intracortical decoding in Canadian patients.
Enrollment: Open for Canadian citizens and residents through the unified Neuralink Patient Registry.
Patient Registry Eligibility & Participation Criteria
The Neuralink Patient Registry is open to individuals aged 18+ (meeting legal age of majority in their jurisdiction) diagnosed with significant neurological conditions, including:
Note: Participation in the registry is voluntary and does not guarantee clinical trial placement. All trial-related surgical procedures, assistive hardware, and clinical follow-up care are fully sponsored by Neuralink.
Institutional Surgical Centers & Official Research Sources
Authorized surgical hospital network and direct official verification links on neuralink.com.
Premier neurosurgical institute executing FDA-cleared IDE trial implantations for the PRIME Study.
Verify via Patient RegistryUniversity Health Network authorized surgical center conducting Health Canada cleared CAN-PRIME trial.
Verify via Canadian Trial RegistryPeer-level technical updates, participant telemetry recordings, and engineering retrospectives.
Read Second Participant Clinical ReportClinical Research Network, Trial Locations & Patient Access
Authorized neurosurgical research hospitals, clinical feasibility studies (PRIME & CAN-PRIME), and patient enrollment protocols.
Investigational Medical Device & Clinical Study Protocol. N1 Link is not a commercially retail-sold consumer product. Implantation access is exclusively conducted under approved FDA Investigational Device Exemption (IDE) clinical protocols.
Clinical participant enrollment actively conducted at premier neurological research hospitals in the United States and Canada (PRIME and CAN-PRIME studies). Pre-regulatory dialogues underway with UK and European health authorities.
Direct operations, infrastructure clearance, and institutional support.
Authorized Clinical Surgical Centers & Research Sites
United States
Active CoverageJurisdictions / Corridors: United States (FDA IDE trial sites including Barrow Neurological Institute, Phoenix, Arizona)
Hubs & Infrastructure: FDA-cleared institutional review board (IRB) clinical research partner centers for quadriplegia participants
Canada
Active CoverageJurisdictions / Corridors: Canada (Health Canada authorized CAN-PRIME study)
Hubs & Infrastructure: University Health Network (UHN) / Toronto Western Hospital authorized surgical center
Clinical Trial Protocols, Patient Rights & Coverage Guarantees
Zero Cost for Enrolled Clinical Trial Participants
100% SponsoredAll neurosurgical procedures, R1 robotic insertions, N1 wireless hardware, post-operative clinical monitoring, and neuro-rehabilitation are 100% sponsored and funded by Neuralink.
Open Patient Registry Recruitment
Patient RegistryIndividuals residing in the United States and Canada with quadriplegia, paraplegia, vision loss, or ALS can register online via the official Neuralink Patient Registry for active and upcoming trials.
FDA Breakthrough Device Designation for Blindsight
FDA BreakthroughGranted expedited FDA review for the Blindsight visual cortical interface project, designed to bypass damaged ocular nerves and restore visual perception to the blind.
Participant Engineering Support & Assistive Technology Programs
Continuous Individualized Engineering Support
Dedicated neuro-engineering teams provide participants with custom control profiles, specialized assistive software integrations, and gaming/productivity interfaces.
Private Capitalization & Neurotech Venture Profile
Private venture funding rounds, breakthrough device valuation, and institutional medical venture partners.
Privately held corporate entity
Private Medical Venture Capital
Series funding round benchmark
Valuation Context & Market Standing
Valued in the $5B–$8B range following a $280M+ Series D venture round led by Founders Fund, with strong demand from life-science and neuro-technology institutional backers.
Elon Musk & Equity Ownership
Privately held and controlled by co-founder Elon Musk alongside neuroscientists, neurosurgeons, and venture capital partners.
Key Institutional Shareholders & Venture Capital Partners
Verified Product Scale & Deployed Fleet Census
Publicly confirmed cumulative manufacturing volumes, active deployed hardware, licensed platforms, and active user metrics for Neuralink.
Neuralink Human Clinical Trial Participants
FDA PRIME / VOICE Trial High-Bandwidth BCI Implant Recipients
Human clinical study participants streaming over 50,000 hours of continuous high-bandwidth intracortical neural decoding for computer control, robotic arm manipulation, and synthetic speech generation.
N1 Telepathy Wireless Cortical Electrode Channels
Biocompatible Flexible Microthread Recording Channels per Implant
Distributed across 64 ultra-thin polyimide microthreads (16 electrodes per thread) inserted into the hand-knob region of the primary motor cortex by the R1 robotic surgical platform, streaming broadband action potentials wirelessly through inductive transcutaneous skin telemetry.
R1 Robotic Surgical Insertion Platforms
Autonomous Sub-Micron Microthread Insertion Surgical Robots
Custom neurosurgical robots featuring 5-axis computer vision and optical coherence tomography (OCT) that autonomously track brain micromotion (breathing/pulse) to insert microthreads with sub-micron precision while completely avoiding cortical blood vessels.
Primary Products & Key Projects
Factual summaries, categories, and technical parameters for Neuralink.
Telepathy (N1 BCI Implant)
Telepathy is Neuralink’s flagship commercial brain-computer interface product. The N1 Implant features 1,024 electrode channels distributed across 64 ultra-fine flexible polymer threads inserted into the motor cortex by the R1 surgical robot. It enables individuals with paralysis to operate digital devices and communicate via decoded intent, with long-term bandwidth projected to exceed human typing or speaking speeds.
R1 Surgical Robot
Because Neuralink’s polyimide threads are thinner than a human hair and cannot be pushed manually without buckling, the R1 Surgical Robot uses a 10–15 µm needle, optical coherence tomography (OCT), and a 5-camera optical stack to track brain surface pulsation and autonomously insert 64 threads to 1.5–2.0 mm cortical depth while routing around surface blood vessels.
Blindsight (Visual Prosthesis)
Blindsight is Neuralink’s second product, designed as an intracortical visual neuroprosthesis that stimulates neurons in the primary visual cortex (V1) to restore visual perception in blind individuals, bypassing damaged eyes and optic nerves. Musk reported the device is engineering-ready pending regulatory review; human clinical trials remain future research plans under the FDA Breakthrough Device Designation program.
PRIME & CAN-PRIME Clinical Trials
The PRIME Study (US) and CAN-PRIME Study (Canada) evaluate the safety and functional utility of the N1 Implant and R1 Robot in individuals with quadriplegia from cervical spinal cord injury or ALS. Conducted at Barrow Neurological Institute in Phoenix, AZ and Toronto Western Hospital (UHN) in Toronto, Ontario, with 100% sponsor-funded clinical care.
Verified Updates for Neuralink
Elon Musk Details Neuralink Product Roadmap: Telepathy and Blindsight BCI Applications
On October 30, 2026, Elon Musk publicly outlined Neuralink’s primary product lineup on X, identifying two flagship neural interface products: "Telepathy" and "Blindsight". Telepathy is positioned as Neuralink’s initial commercial product, engineered to enable quadriplegic users to control computers, digital devices, and communicate directly using decoded motor cortex neural signals, with projected bandwidth exceeding human speaking or typing speed in coming years. The second product, "Blindsight", is an intracortical visual neuroprosthesis designed to restore visual perception in blind individuals by directly stimulating the primary visual cortex (V1); Musk indicated the hardware is engineering-ready pending regulatory review. Neuralink’s official website maintains that visual prosthesis clinical trials remain future research plans and invites interested participants to enroll in the patient registry; prior FDA Breakthrough Device Designation does not constitute immediate human clinical trial authorization or commercial market clearance.
Neuralink Reaches 50,000+ Hours of Clinical BCI Neural Data Streaming Milestone
Neuralink announced that human clinical trial participants have collectively streamed over 50,000 hours of continuous neural recording data. The extensive dataset is powering patient-specific neural decoding algorithms, significantly reducing daily calibration time and establishing new communication bandwidth benchmarks.
Neuralink Demonstrates Speech Restoration in Third Participant (Terry) via VOICE Trial
Neuralink released clinical video documentation demonstrating Terry, the third participant in the VOICE clinical trial living with ALS, producing audible synthesized speech directly decoded from neural signals via a high-density 3,000-channel brain implant.